Diffusion Pharmaceuticals

Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen. The firm's product candidate, Trans Sodium Crocetinate, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. The company was founded in1995 and is headquartered in Boston, MA.

Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) shares were more than doubling Wednesday following an announcement by the company regarding testing of its lead asset for COVID-19-related complications.

Diffusion Pharma To Evaluate Drug In COVID-19-Related Respiratory Distress, Sending Stock Higher

Partnering with University of Virginia Health and iTHRIV Partnering with University of Virginia Health and iTHRIV

Diffusion Pharmaceuticals Evaluating TSC Against Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients

Overtaxed healthcare systems will delay enrollment in some geographic locations Overtaxed healthcare systems will delay enrollment in some geographic locations

Diffusion Pharmaceuticals Anticipates Enrollment in its Ambulance-based Stroke Trial Will be Slowed Due to the Impact of the Coronavirus

Dr. Gainer to remain on board of directors Dr. Gainer to remain on board of directors

Diffusion Pharmaceuticals Announces Retirement of Chief Science Officer John L. Gainer

CHARLOTTESVILLE, Va., Feb.  07, 2020  (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced that it has been granted Patent Number EP2540696 B1 from the European Patent Office. This patent relates to pharmaceutical compositions of trans sodium crocetinate (“TSC”) and a cyclodextrin for use in therapy.  Specifically claimed are TSC compositions are for use in conjunction with radiation or chemotherapy.  Secondary claims relate to various compositions of TSC.

Diffusion Pharmaceuticals Receives European Patent Related Compositions of TSC

CHARLOTTESVILLE, Va., Jan.  10, 2020  (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, announces the appointment of Robert Cobuzzi, Jr., Ph.D., 55, to the Company’s board of directors, effective immediately. 

Diffusion Pharmaceuticals Appoints Life Sciences Veteran Dr. Robert Cobuzzi, Jr.

CHARLOTTESVILLE, Va., Dec.  13, 2019  (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) today announced the closing of its previously announced registered direct offering, priced at-the-market, with certain institutional investors of 6,266,787 shares of the Company’s common stock, at a purchase price of $0.5585 per share and associated warrant. The Company also issued 6,266,787 unregistered warrants to the institutional investors in a concurrent private placement to purchase one share of common stock for each share of common stock purchased with an exercise price of $0.4335 per share. The gross proceeds to Diffusion, before deducting placement agent fees and other offering expenses, were approximately $3.5 million. The warrants are exercisable upon issuance and will expire five and one half years following the date of issuance.

Diffusion Pharmaceuticals Inc. Announces Closing of $3.5 Million Offering Priced At-the-Market

CHARLOTTESVILLE, Va., Dec.  12, 2019  (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), please note that the pricing and figures in the first paragraph of the release have changed. The corrected release follows:

CORRECTING and REPLACING – Diffusion Pharmaceuticals Inc. Announces $3.5 Million Registered Direct Offering Priced At-the-Market

Presentation Made by Chief Scientific Officer John Gainer at the Inaugural Glioblastoma Drug Development Summit Presentation Made by Chief Scientific Officer John Gainer at the Inaugural Glioblastoma Drug Development Summit

Diffusion Pharmaceuticals Presents Data Suggesting Optimized TSC Dosing Regimen Increases Survival in Newly Diagnosed Inoperable Glioblastoma Patients

Diffusion Pharmaceuticals is a tiny micro-cap with market cap between $4.6m and $11.1m (based on a price of $0.285), developing an add-on treatment for brain cancer (glioblastoma) and stroke.

Diffusion Pharmaceuticals' TSC: Thoughts On The Potential For Its Glioblastoma Indication

Chief Scientific Officer Dr. John Gainer to Present at Inaugural Glioblastoma Drug Development Summit Chief Scientific Officer Dr. John Gainer to Present at Inaugural Glioblastoma Drug Development Summit

Diffusion Pharmaceuticals Presents Early Findings Showing Increased Survival in Lead-in Portion of Phase 3 Glioblastoma Study with TSC plus Standard of Care

CHARLOTTESVILLE, Va., Nov.  15, 2019  (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) a clinical-stage biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced the closing of its previously announced public offering of an aggregate of 11,428,572 shares of common stock (or common stock equivalents) of the Company, together with accompanying common warrants, at a public offering price of $0.35 per share and associated warrants. Each share of common stock (or common stock equivalent) sold in the offering was sold collectively with (i) a common warrant to purchase one share of common stock expiring eighteen months from the date of issuance and (ii) a common warrant to purchase one share of common stock expiring five years from the date of issuance. Each common warrant has an exercise price of $0.35.

Diffusion Pharmaceuticals Announces Closing of $4.0 Million Public Offering

CHARLOTTESVILLE, Va., Nov.  13, 2019  (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or the “Company”), a clinical-stage biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced that it has priced a public offering of an aggregate of 11,428,572 shares of common stock (or common stock equivalents) of the Company, together with accompanying common warrants, at a public offering price of $0.35 per share and associated warrants.  Each share of common stock (or common stock equivalent) sold in the offering was sold collectively with (i) a common warrant to purchase one share of common stock expiring eighteen months from the date of issuance and (ii) a common warrant to purchase one share of common stock expiring five years from the date of issuance. Each common warrant has an exercise price of $0.35.

Diffusion Pharmaceuticals Announces $4.0 Million Public Offering

CHARLOTTESVILLE, Va., Oct.  17, 2019  (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, announces that the first patient has been enrolled in its Phase 2 on-ambulance study evaluating trans sodium crocetinate (TSC) for the treatment of stroke.  The 160-patient trial, named PHAST-TSC (Pre-Hospital Administration of Stroke Therapy-TSC), will involve 23 hospitals, working closely with approximately 150 emergency medical transport groups across Central Virginia and urban, suburban and rural areas in Los Angeles County. Results from the trial may be available in just under two years.

First Patient Enrolled in Diffusion Pharmaceuticals’ Phase 2 On-Ambulance Clinical Trial with TSC for the Treatment of Stroke

CHARLOTTESVILLE, Va., Sept.  03, 2019  (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced that management will present at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 4:40 p.m. Eastern Time. The conference will be held September 8-10 at the Lotte New York Palace Hotel in New York City.

Diffusion Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference

ElectroCore Inc

Spherix

Year to date, the market has gifted investors a 9.92% return, but it remains off 5.73% from the start of the fourth quarter. While many investors are enjoying a lift in their stocks, the Ben Graham Screener, which finds net-nets, has been active.

News for Diffusion Pharmaceuticals Stock (DFFN)